Bio-Rad Laboratories, Inc. (BIO) Cash Flow Statement

The gap between net income and operating cash flow is extreme in several quarters, with OCF/NI ratios ranging from negative values to above 2.0 in Q1 2025. This pattern suggests reported net income is being driven by non-cash mark-to-market movements tied to the Sartorius stake rather than by core operating activity. Investors should treat operating cash flow as the more reliable indicator of underlying cash generation, while recognizing that its stable level implies the core business generates modest but consistent cash.

The downward drift in FCF margin appears to reflect lower operating cash generation relative to a flat top line, consistent with the gross margin compression noted in the prior income statement review. With trailing revenue growth of only 0.7%, the decline suggests the core business is not yet converting stable sales into expanding cash flow. Investors should monitor whether the Q3 2026 FCF of $65M marks a trough or the start of a sustained lower base.

Capex intensity at these levels suggests the company is not in a heavy reinvestment phase, which supports free cash generation relative to operating cash flow. Depreciation and amortization of roughly $36M to $49M per quarter is broadly comparable to capex in most periods, which may indicate the asset base is being maintained without meaningful expansion. This pattern warrants further investigation into whether restrained reinvestment could weigh on the long-term competitive position of the ddPCR platform.

The absence of a dividend and the intermittent buyback pattern suggest management is prioritizing balance sheet flexibility over shareholder distributions, consistent with its conservative family-controlled posture. Cash deployed to acquisitions has been minimal aside from a $216.6M outflow in Q2 2025, which may indicate a deliberate pause in M&A. Investors should monitor whether accumulated cash is eventually returned or redeployed, as current capital allocation intentions remain unclear from the reported data.

Summing ten quarters of reported net income produces a figure dominated by a single large non-cash charge, making the cumulative earnings picture unrepresentative of the underlying business. Cumulative operating cash flow tells a more stable story of consistent cash generation. The divergence suggests headline earnings should not be used to judge the company's cash earning power, and investors should anchor valuation to operating cash flow adjusted for Sartorius effects.